Cargando…
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
Treatment discontinuation is considered one of the main goals of therapy for patients with chronic myeloid leukemia. Several criteria are felt to be necessary to consider discontinuation, while others may predict a better chance of achieving treatment-free remission. Criteria for discontinuation inc...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716356/ https://www.ncbi.nlm.nih.gov/pubmed/33054106 http://dx.doi.org/10.3324/haematol.2019.242891 |